What FDA Should Do With Next-Gen Sequencing in Clinical Labs

AMP today said that overwrought or misguided regulation for using next-generation sequencing in the clinical lab could "limit the practice of medicine," and called for "flexible and individualized" protocols, guidelines, and controls."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.